Abstract-Brain renin-angiotensin system hyperactivity has been implicated in the development and maintenance of hypertension. We reported previously in the brain that aminopeptidase A and aminopeptidase N are involved in the metabolism of angiotensin II and angiotensin III, respectively. By using in vivo specific and selective aminopeptidase A and aminopeptidase N inhibitors, we showed that angiotensin III is one of the main effector peptides of the brain renin-angiotensin system, exerting a tonic stimulatory control more than blood pressure in hypertensive rats. Aminopeptidase A, the enzyme generating brain angiotensin III, thus represents a potential target for the treatment of hypertension. We demonstrated here the antihypertensive effects of RB150, a prodrug of the specific and selective aminopeptidase A inhibitor, EC33, in spontaneously hypertensive rats, a model of human essential hypertension. Oral administration of RB150 in conscious spontaneously hypertensive rats inhibited brain aminopeptidase A activity, demonstrating the central bioavailability of RB150 and its ability to generate EC33 into the brain. Oral RB150 treatment dose-dependently reduced blood pressure in spontaneously hypertensive rats with an ED 50 of 30 mg/kg, lasting for several hours. This decrease in blood pressure is partly attributed to a decrease in sympathetic tone, reducing vascular resistance. This treatment did not modify systemic renin-angiotensin system activity. Concomitant oral administration of RB150 with a systemic renin-angiotensin system blocker, enalapril, potentiated the RB150-induced blood pressure decrease achieved in Ͻ2 hours. Thus, RB150 may be the prototype of a new class of centrally active antihypertensive agents that might be used in combination with classic systemic renin-angiotensin system blockers to improve blood pressure control. (Hypertension. 2012;60:00-00.) • Online Data Supplement Key Words: aminopeptidase A inhibitors Ⅲ blood pressure Ⅲ brain renin-angiotensin system Ⅲ spontaneously hypertensive rats Ⅲ hypertension D espite the availability of Ͼ75 antihypertensive agents, high blood pressure (BP) remains difficult to control. Many patients will require 2 or even 3 drugs to control their BP.
D
espite the availability of Ͼ75 antihypertensive agents, high blood pressure (BP) remains difficult to control. Many patients will require 2 or even 3 drugs to control their BP. 1 Resistant hypertension to Ն3 antihypertensive drugs (including a diuretic) occurs in 15% of the hypertensive population. The current antihypertensive agents are also less effective in patients of African ancestry 2, 3 or those with diabetes mellitus or renal insufficiency. [4] [5] [6] Consequently, there is a need to develop new classes of antihypertensive agents with different mechanisms of action to improve BP control and the associated cardiovascular risks.
It has been suggested that there may be a central component involved in hypertension based on the sympathetic hyperactivity observed in the early stages of this pathology. 7 Indeed, overactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and the maintenance of hypertension in several types of experimental and genetic hypertension animal models, such as spontaneously hypertensive rats (SHRs), deoxycorticosterone acetate (DOCA)-salt hypertensive rats, [8] [9] [10] or transgenic mice overexpressing both human angiotensinogen and human renin. 11, 12 This results in the brain in an increased angiotensinogen gene expression, 13 elevated renin and angiotensin II (Ang II) and angiotensin III (Ang III) levels, 14, 15 an upregulation of Ang II turnover, 9 an overexpression of Ang II receptors, 16 and an increased sympathetic neuron activity 17 or arginine-vasopressin (AVP) release. 18 In contrast, plasma renin activity (PRA) used as a marker of the activity of the systemic RAS is normal in the SHR model, whereas it is depressed in DOCA-salt rats and increased in transgenic animals. [19] [20] [21] We reported previously 22 that, in the brain RAS, aminopeptidase A (APA; EC 3.4.11.7), a membrane-bound zinc metalloprotease, removes in vivo the N-terminal aspartate of Ang II (Ang 1-8) to generate Ang III (Ang 2-8), whereas aminopeptidase N (EC 3.4.11.2), another membrane-bound zinc metalloprotease, removes the N-terminal arginine of Ang III to generate angiotensin IV (Ang 3-8; Figure 1 ). By using specific and selective APA and aminopeptidase N inhibitors, EC33 and PC18, respectively, 23, 24 we demonstrated that Ang III is one of the main effector peptides of the brain RAS in the control of AVP release and BP. 20, 22, [25] [26] [27] Brain Ang III exerts a tonic stimulatory effect on the control of BP in conscious SHRs, an experimental model of essential hypertension sensitive to RAS blockers, and in DOCA-salt rats, a salt-and volumedependent model of hypertension, resistant to systemic RAS blockers. 20, 25, 28 Therefore, the inhibition of central but not peripheral APA with EC33 reduces brain Ang III levels leading to a decrease in BP in DOCA-salt rats 20 and SHRs. 25 Therefore, brain APA constitutes a promising therapeutic target for the treatment of certain forms of hypertension, which justifies the development of potent and selective APA inhibitors as centralacting antihypertensive agents. However, because EC33 does not cross the blood-brain barrier (BBB), 25 ,29 a systemically active prodrug of EC33, 4,4=-dithio (bis[{3S}-3-aminobutyl sulfonic acid]; RB150) 20, 29 was designed. RB150 is a dimer of EC33, generated by creating a disulfide bond (Figure 1 ). RB150 does not inhibit APA activity, because in this molecule the thiol group of EC33 is engaged in a disulfide bridge and is unable to interact with the zinc atom present in the APA active site and essential for APA catalytic activity. 30, 31 However, this bridge allows RB150 injected systemically to cross the BBB and enter the brain. Once in the brain, the disulfide bridge of RB150 is cleaved by brain reductases generating 2 active molecules of EC33, which block brain APA activity. 20, 29 Accordingly, RB150 given by oral route to conscious DOCA-salt rats was shown to enter the brain, induce a sustained inhibition of brain APA activity, and block brain Ang III formation, thereby normalizing BP. 20, 29 In this model, RB150 also decreased plasma AVP levels, increased diuresis, and induced a mild natriuresis, without affecting kaliuresis, thereby reducing blood volume participating to BP decrease. 29 Thus, RB150 could represent the prototype of a new class of centrally acting antihypertensive agents. For this purpose, this study was designed to extend the findings obtained with RB150 in the DOCA-salt rat to other hypertension models, such as the SHR, to further validate the therapeutic potential of brain APA targeting in cardiovascular diseases. We thus assessed in SHRs whether RB150 given by oral route crosses the BBB, inhibits brain APA activity, and significantly lowers BP. With the aim to better understand in SHRs the mechanism of action of RB150 on BP, we investigated the effects of RB150 oral administration both on blood volume by measuring water intake, diuresis, and urinary electrolytes and on sympathetic neuron activity by measuring BP after ganglionic blockade. In parallel, we also assessed the effects of RB150 administration on the systemic RAS activity by measuring PRA. Finally, we studied in SHRs whether concomitant oral administration of RB150 with a systemic RAS blocker, enalapril, could be useful for normalizing BP.
Methods
All of the procedures in this study were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male Wistar-Kyoto (WKY) rats and SHRs were randomly assigned to oral saline, RB150 (from 15 to 150 mg/kg), enalapril (3 mg/kg), or RB150 (100 mg/kg) plus enalapril (1 mg/kg) treatment groups. Another set of rats were treated with hexamethonium (HEX; 20 mg/kg, IP) alone or combination with RB150 (150 mg/kg, PO). Toxicity studies were performed with Sprague-Dawley rats and with Beagle dogs. We performed the following experimental procedures: APA enzymatic activity measurement, BP measurement, urine and electrolyte output and fluid consumption, determination of PRA, toxicity studies, and statistical analysis. For an expanded methods section, see the online-only Data Supplement. Figure 2A ). However, RB150 treatment reduced by 58% the increase in APA activity in SHRs compared with normotensive WKY rats (⌬ II versus ⌬ I ; Figure 2A ). As shown previously, 29 
Results
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Effects of Oral RB150 Administration on BP and Heart Rate in Conscious SHRs
Basal mean arterial BP (MABP) of conscious SHRs (173.0Ϯ2.6 mm Hg; nϭ32) was significantly higher than that of normotensive WKY rats (105.2Ϯ4.1 mm Hg; nϭ5). Basal heart rate (HR) was 345.1Ϯ6.2 bpm in SHRs and 371.0Ϯ15.5 bpm in normotensive WKY rats. No significant difference in baseline MABP and HR was found between the different groups of SHRs used in this study. Oral administration of RB150 (from 15 to 150 mg/kg) dose-dependently decreased MABP in conscious SHRs, with an ED 50 of 30.5 mg/kg ( Figure 2B and Table S1 ), without altering significantly HR (Table S1 ). A maximal decrease in MABP (Ϫ37.2Ϯ8.0 mm Hg) was observed at a dose of 150 mg/kg. The hypotensive effect for each dose studied (from 15 to 150 mg/kg) began 2 to 3 hours after administration, was maximal between 5 and 6 hours, and disappeared after 24 hours ( Figure 2C ). The oral administration of saline in conscious SHRs, used as an internal control, did not significantly alter MABP or HR, regardless of the time elapsed between administration and recording (between 0 and 24 hours). Interestingly, 5 hours after oral administration, RB150 (15 mg/kg) had no significant effect on MABP or HR in conscious normotensive WKY rats (Table S1 ). The maximal decrease in MABP (Ϫ23.0Ϯ2.9 mm Hg) induced by RB150 (50 mg/kg, PO) in conscious SHRs was similar to that (Ϫ26.5Ϯ4.8 mm Hg) induced by enalapril (3 mg/kg, PO; Table S1 ). The maximal effect on MABP was measured 5 hours after the oral administration of enalapril versus 6 hours with RB150 and totally disappeared in both treatments after 24 hours.
Effects of Concomitant Acute Oral Administration of RB150 With Enalapril on BP and HR in Freely Moving SHRs
Concomitant oral administration of RB150 (100 mg/kg) with enalapril (1 mg/kg) significantly and markedly decreased MABP 
Effects of Acute Oral RB150 Administration and Ganglionic Blockade on BP and HR in Freely Moving SHRs
Acute IP injection of HEX (20 mg/kg; nϭ7) in conscious SHRs elicited rapid, reversible decreases in MABP ( Figure  4A and 4B) accompanied by decreases in HR (data not shown). Maximal decreases in MABP (Ϫ46.5Ϯ4.8 mm Hg) and HR (Ϫ45.1Ϯ22.4 bpm) were observed 20 minutes after the injection ( Figure 4B ). The next day, alert SHRs were submitted to acute oral treatment with RB150 (150 mg/kg), and a maximal decrease in MABP (Ϫ24.1Ϯ2.6 mm Hg) was observed 6 hours after treatment without any significant modification of HR (data not shown). The absolute levels of BP in RB150-or saline-treated SHRs, 6 hours after oral administration, were 141.5Ϯ2.9 and 162.2Ϯ3.7 mm Hg, respectively. At this time, HEX (20 mg/kg; IP) treatment significantly decreased BP in RB150-treated rats (124.8Ϯ7.8 mm Hg), as well as in saline-treated rats (115.7Ϯ6.8 mm Hg), during the entire period of BP recording (60 minutes). RB150 pretreatment decreased by 64% the maximal hypotensive effect observed after ganglionic blockade with HEX (Ϫ16.7Ϯ8.1 mm Hg in HEXϩRB150-treated SHR versus Ϫ46.5Ϯ4.8 mm Hg in HEXϩsaline-treated SHRs) and delayed it by 10 minutes ( Figure 4B ).
Effects of Oral Administration of RB150 on PRA in WKY Rats and SHRs
As shown in Figure S1 , no significant difference in PRA was observed between saline-treated WKY rats and SHRs (3.15Ϯ0.13 versus 2.63Ϯ0.37 ng of angiotensin I produced per milliliter of plasma per hour; nϭ8 in each group). The PRAs of the different experimental groups were comparable to those reported previously. 32 Moreover, oral administration of RB150 (100 mg/kg; nϭ8) in SHRs did not have any significant effect on PRA as compared with SHRs receiving an oral saline administration (3.30Ϯ0.39 versus 3.15Ϯ0.13 ng of angiotensin I produced per milliliter of plasma per hour; Figure S1 ).
Effects of Oral RB150 Administration in Conscious SHRs on Water Intake, Diuresis, Natriuresis, and Kaliuresis
The values measured for water intake, diuresis, and urinary electrolytes in WKY rats and SHRs are consistent with previous studies. 33 As shown in Figure S2 , in normotensive WKY rats, oral treatment with RB150 (50 mg/kg; nϭ10) did not modify significantly water intake, diuresis, natriuresis, and kaliuresis for a 5-hour analysis as compared with oral saline treatment. Although water intake and natriuresis were similar in saline-treated WKY rats and SHRs ( Figure S2A and S2C ), diuresis and kaliuresis were significantly lower in saline-treated SHRs as compared with saline-treated WKY rats ( Figure S2B and S2D) . In SHRs receiving oral RB150 (50 mg/kg; nϭ5) administration, no significant change for water intake, diuresis, natriuresis, or kaliuresis for a 5-hour analysis was observed as compared with SHRs receiving saline ( Figure  S2 ). The oral administration of RB150 (150 mg/kg; nϭ5) in SHRs did not induced any significant change in water intake (29. Toxicity Studies With RB150 in the Rat and the Dog RB150 administered daily by oral route for 28 consecutive days at the doses of 125 and 550 mg/kg did not induce mortality or major signs of toxicity in Sprague-Dawley rats. When administered at 1000 mg/kg, although the cause of the death of 1 male and 1 female remain unclear, RB150 did not induce any sign of toxicity (Table S2) . In Beagle dogs, RB150 administered daily by the oral route for 28 consecutive days at the doses of 125, 500, and 1000 mg/kg did not induce mortality or major signs of toxicity except diarrhea observed at the doses of 500 and 1000 mg/kg in male and female dogs (Table S2 ). Nevertheless, diarrhea was not associated with body weight loss. For both animal species, body weight, food intake, drinking behavior, diuresis, and urine osmolality were not significantly modified (Table S2) . Chronic treatment with RB150 (from 125 to 1000 mg/kg per day, PO) during 28 days had no effect on systolic BP in Beagle dogs, as shown in Table S3 . Taken together, the no-observed adverse effect level after 28-day repeated oral administration corresponded with Ն550 mg/kg in the rat and 1000 mg/kg in the dog.
Discussion
This study describes a new pharmacological approach for lowering BP in SHRs. This approach is based on the oral administration of the APA inhibitor prodrug, RB150, that was shown previously to block in DOCA-salt rats the brain RAS activity. After its oral administration in SHRs, RB150 crosses the gastrointestinal barrier, enters the brain, and generates 2 active molecules of the specific and selective APA inhibitor EC33. The latter blocks brain APA activity, preventing brain Ang III formation, and induces a marked BP decrease in conscious SHRs without changing HR. The RB150-induced BP decrease is in part mediated by an inhibition of sympathetic neuron activity, because the decrease in BP induced by ganglionic blockade with HEX is highly reduced by RB150 pretreatment. In contrast, oral RB150 treatment does not modify systemic RAS activity. However, both blocking the activity of the brain and systemic RAS by concomitant oral administration of RB150 with enalapril potentiates the RB150-induced BP decrease in SHRs.
Overactivity of the brain RAS was shown to play a critical role in mediating hypertension in SHRs. 9, [14] [15] [16] In several brain nuclei, APA activity was significantly higher in SHRs than in WKY rats. 34 In agreement with these data, the present study showed that APA enzymatic activity in the whole brain of SHRs was like that in DOCA-salt rats, 20,29 increased by 2.2 times as compared with brain APA activity in normotensive rats. This strongly suggests a participation of APA in the RAS hyperactivity of the SHR brain. Blockade of brain angiotensin receptors in SHRs 35 and pharmacological interference with brain angiotensin formation 33, 36 decreases arterial BP to normal levels. We showed previously that the blockade of endogenous brain Ang III formation by the ICV injection of the APA inhibitor EC33 alone markedly decreased BP in alert SHRs. 25 In contrast, EC33 given alone by IV route, even at a high dose, did not modify BP in alert SHRs. 25 Together, these data show that the blockade of the formation of brain but not systemic Ang III by EC33 is responsible for the decrease in BP.
In such a context, APA inhibitors able to cross the BBB after oral administration and to block the brain RAS activity appear as innovative antihypertensive agents. We, thus, developed RB150, an orally active prodrug of EC33, which enters the brain, inhibits brain APA activity, and blocks brain Ang III formation 20, 29 ( Figure 5 ). This molecular mechanism was further confirmed by a distribution and metabolite profiling study performed in male Sprague-Dawley rats treated with tritiated RB150; whereas radioactivity was found in brain samples collected from rats treated with tritiated RB150, EC33 but not RB150 could be detected, suggesting that RB150 is immediately converted to EC33 in the brain (data not shown). The selectivity of EC33 and RB150 toward APA was shown previously 29 by the lack of affinity of these compounds for other zinc metalloproteases involved in the production or metabolism of vasoactive peptides, such as aminopeptidase N, angiotensin I-converting enzyme, angiotensin-converting enzyme type 2, endothelin-converting enzyme 1, and neutral endopeptidase 24.11, as well as by the absence of binding of these compounds to angiotensin or endothelin receptors known to be involved in BP regulation. Consistent with these data, acute oral administration of RB150 (100 mg/kg) in SHRs resulted in a significant inhibition of brain APA activity 3.5 hours after treatment. In these conditions, APA overactivity observed in SHRs is reduced by 58% compared with control levels measured in normotensive WKY rats. Direct comparison of the inhibition of brain APA 
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Orally Active APA Inhibitors and Hypertensionactivity found in SHRs after oral RB150 administration with the dose-response inhibition curve obtained after the ICV administration of EC33 20 suggests that 0.1% of the prodrug penetrates the brain. This value is 10 times lower than that obtained in DOCA-salt rats after similar RB150 oral administration 29 and may be attributed to a more permeable BBB in DOCA-salt rats compared with that of SHRs because of the presence of mineralocorticoid and salt in drinking water, as shown previously. 37, 38 The inhibition of brain APA activity in conscious SHRs after oral administration of RB150 (100 mg/kg corresponding with a concentration of 80 nmol in brain) resulted in a 27-mm Hg decrease in BP, equivalent to that observed with EC33 20 (150 nmol, ICV). This hypotensive effect was dose dependent with an ED 50 of 30 mg/kg. The dose of 150 mg/kg PO induced a maximal 37-mm Hg decrease in BP. The RB150-induced decrease in BP was large and long lasting, but HR was not significantly affected, suggesting that the sensitivity of the baroreflex was decreased by brain Ang III, consistent with the findings of Lin et al 39 on the involvement of endogenous angiotensins in tonic baroreflex suppression. Our results highlight the efficiency of oral RB150 administration to inhibit brain APA activity and to decrease BP several hours without changing HR in SHRs, as shown previously in DOCA-salt rats. 20, 29 The RB150 hypotensive effect was effective only at higher doses in the SHR (ED 50 , 30 mg/kg) compared with the DOCA-salt rat (ED 50 , 1 mg/kg), presumably because of a less favorable pharmacokinetics profile of RB150 in the SHR. Nevertheless, toxicology, safety pharmacology, and pharmacokinetics studies performed in animals have demonstrated that RB150 is well tolerated both in rats (no-observed adverse effect level, 550 mg/kg) and dogs (no-observed adverse effect level, 1000 mg/kg) at doses significantly superior to the dose showing antihypertensive activity in rats. RB150 was also shown to have a better bioavailability in dogs than in rats (data not shown).
We also found that RB150 (50 mg/kg) was as efficient as the angiotensin I-converting enzyme inhibitor enalapril (3 mg/kg), which is currently used clinically for treatment of hypertension. Both compounds showed 20-to 26-mm Hg reductions in BP. Moreover, RB150 (100 mg/kg, PO) in SHRs did not have any significant effect on PRA compared with SHRs receiving oral saline, suggesting that RB150 does not modify the systemic RAS activity. Consequently, we can hypothesize that synergy and improvement in BP control of hypertensive patients can be found by combining RB150 with an angiotensin I-converting enzyme inhibitor or an Ang II type 1 receptor antagonist, because both the brain and the systemic RAS would be inhibited. In agreement with this hypothesis, we showed presently in SHRs that concomitant oral administration of RB150 with enalapril potentiated the RB150-induced decrease in BP as compared with BP decrease induced by RB150 or enalapril alone. This was particularly well illustrated at short-time treatment; whereas RB150 at the dose of 100 mg/kg or enalapril at the dose of 1 mg/kg did not induce any significant change in BP 1 hour after oral administration, a significant hypotensive effect (Ϫ16.4Ϯ3.08 mm Hg) occurred with the combination of the 2 compounds.
The brain RAS controls BP via 3 different mechanisms 40 : (1) activating sympathetic neuron activity in the rostral ventrolateral medulla; (2) synaptic inhibition of the baroreflex in the nucleus of the tractus solitarius; and (3) increase in the release of AVP from the posterior pituitary into the blood circulation ( Figure 5 ). All of these structures were known to contain APA activity, Ang II type 1 receptor binding sites, and angiotensinergic nerve terminals. 41 It is now well established that SHRs exhibit an increase in sympathetic neuron activity, which participates in the development and maintenance of hypertension in this model. 17 Consistent with the mechanism of action of the brain RAS in BP control, RB150 given PO to SHRs seems to decrease sympathetic neuron activity, as shown by the significant decrease of the hypotensive effect of HEX, a ganglionic blocker, 42 in RB150-pretreated SHRs as compared with saline-pretreated SHRs, although vascular effects cannot be totally excluded. However, recent data obtained in collaboration with the laboratory of Huang et al 43 strengthened this conclusion by showing that ICV infusion of RB150 during 28 days in rats postmyocardial infarction drastically reduced the electric activity of the sympathetic renal nerve, attenuating sympathetic overactivity occurring in this model. RAS hyperactivity observed in SHR brain, partly because of a greater APA activity 34, 44 in brain structures known to control sympathetic neuron activity (paraventricular nucleus, nucleus of the tractus solitarius, and rostral ventrolateral medulla), results in an increased sympathetic tone 10, 45 and may account for the efficiency by which APA inhibitors decreased sympathetic tone and BP in this model.
In rodents, Ang III injected ICV but not Ang II was shown to increase systemic AVP release, resulting in a reduced diuresis. 22 In contrast to DOCA-salt rats, 29 no significant change was observed in diuresis in SHRs after oral RB150 administration. This is probably because of the fact that no increase in vasopressinergic neuron activity occurs in this genetic model of hypertension.
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Perspectives
RB150 is the first orally active molecule able of inhibiting brain RAS without affecting systemic RAS activity. RB150 strongly reduces BP several hours after a single administration, without changing HR in an experimental model of essential hypertension, as in an experimental salt-dependent model of hypertension. Centrally acting APA inhibitors may, therefore, constitute a new class of antihypertensive agents. They could contribute alone or in combination with a systemic RAS blocker to improve BP control and reduce cardiovascular risks in patients. RB150 appears as the first prototype of this potentially novel class of drugs and so far as a very promising drug candidate. Because RB150 (also named QGC001) has obtained the approval from the French health authorities for the first clinical trial in humans, future clinical investigations with this compound in healthy volunteers and patients should bring a better understanding of the role of APA and brain RAS in the development and the maintenance of hypertension in humans.
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Novelty and Significance
What Is New?
• RB150/QGC001 is the prototype of a new class of centrally acting antihypertensive agents, contributing to improve BP. Its action is based on a new concept of brain enzyme inhibition.
What Is Relevant?
• RB150 is a very promising drug candidate for treatment of hypertension. It received on January 5, 2012, the approval from health authorities for the first clinical trial in humans.
Summary
RB150 alone or in combination with enalapril induces a strong reduction of BP in SHRs by inhibiting brain and/or systemic RAS activity. Table S2 . Toxicity studies with RB150 in the rat and the dog. Animals were treated daily during 28 days with RB150 (125, 550 or 1000mg/kg, PO) and different parameters were measured as described in supplemental methods. Figure S2. Effects of oral administration of RB150 on water intake, urinary excretion of water, natriuresis and kaliuresis in WKY and SHR. After 3 days of acclimatization to metabolic cages, WKY (white bar) and SHR (grey bar) were treated with RB150 (50 mg/kg) or saline. Then, they were returned to the metabolic cages for the measurement of water intake (A), diuresis (B), natriuresis (C), and kaliuresis (D) over a 5-hours period. Mean±SEM of 5 to 10 animals individually analyzed for each condition; ANOVA; * P <0.05, WKY receiving saline vs SHR receiving saline.
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